Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 Jul;24(7):521-542.
doi: 10.1038/s41573-025-01164-x. Epub 2025 Mar 18.

Computational drug repurposing: approaches, evaluation of in silico resources and case studies

Affiliations
Review

Computational drug repurposing: approaches, evaluation of in silico resources and case studies

Ziaurrehman Tanoli et al. Nat Rev Drug Discov. 2025 Jul.

Abstract

Repurposing of existing drugs for new indications has attracted substantial attention owing to its potential to accelerate drug development and reduce costs. Hundreds of computational resources such as databases and predictive platforms have been developed that can be applied for drug repurposing, making it challenging to select the right resource for a specific drug repurposing project. With the aim of helping to address this challenge, here we overview computational approaches to drug repurposing based on a comprehensive survey of available in silico resources using a purpose-built drug repurposing ontology that classifies the resources into hierarchical categories and provides application-specific information. We also present an expert evaluation of selected resources and three drug repurposing case studies implemented within the Horizon Europe REMEDi4ALL project to demonstrate the practical use of the resources. This comprehensive Review with expert evaluations and case studies provides guidelines and recommendations on the best use of various in silico resources for drug repurposing and establishes a basis for a sustainable and extendable drug repurposing web catalogue.

PubMed Disclaimer

Conflict of interest statement

Competing interests: A.F.-T., I.G.G., R.G.-S., J.Q. and J.M. are employees of Chemotargets, a partner of the REMEDi4ALL project. ClarityVista is a software platform developed by Chemotargets. J.C.-P. and O.S. declare ownership in Phenaros Pharmaceuticals AB. T.C. and A.R.B. are employees of Dompé farmaceutici SpA, a partner of the REMEDi4ALL project. All the other authors declare no competing interests.

Similar articles

Cited by

References

    1. Schuhmacher, A., Hinder, M., Von Stegmann Und Stein, A., Hartl, D. & Gassmann, O. Analysis of pharma R&D productivity – a new perspective needed. Drug Discov. Today 28, 103726 (2023). - DOI - PubMed
    1. Wouters, O. J., McKee, M. & Luyten, J. Estimated research and development investment needed to bring a new medicine to market, 2009–2018. JAMA 323, 844–853 (2020). - PMC - DOI - PubMed
    1. Paul, S. M. et al. How to improve R&D productivity: the pharmaceutical industry’s grand challenge. Nat. Rev. Drug Discov. 9, 203–214 (2010). - DOI - PubMed
    1. Dowden, H. & Munro, J. Trends in clinical success rates and therapeutic focus. Nat. Rev. Drug Discov. 18, 495–496 (2019). - DOI - PubMed
    1. Batta, A., Kalra, B. S. & Khirasaria, R. Trends in FDA drug approvals over last 2 decades: an observational study. J. Fam. Med. Prim. Care 9, 105–114 (2020). - DOI

LinkOut - more resources